You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: 'reverse genome-wide association study' method; genetic links between Familial Mediterranean Fever and ankylosing spondylitis; and more.
A team led by researchers at the University of California, San Francisco generated optical genome maps for 154 individuals from more than two dozen populations.
Sangamo Therapeutics has announced preliminary results from its gene-editing trial, the Associated Press reports.
Cancer Research UK has awarded nearly £60 million in funding to three US investigator-led research initiatives focused on cancer progression and drug response.
In Cell this week: approach for mapping enhancers and their targets, comparative protein interaction analysis of dengue and Zika viruses, and more.
UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.
In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.
In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.
The US Department of Health and Human Services says it has not cancelled a fetal tissue contract with a University of California, San Francisco, lab, Science reports.
The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.